Cohort 2. Age, years 41.0 (10.2) Diabetes duration, years 26.5 (15.8)

Similar documents
A novel ph-neutral formulation of the monomeric insulin VIAject has a faster onset of action than insulin lispro

Sponsor: Sanofi Drug substance(s): SAR342434

SYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22

Diabetes Care Publish Ahead of Print, published online June 1, 2009

Novel Formulations to Modify Mealtime Insulin Kinetics

New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Diabetes Care Publish Ahead of Print, published online June 22, 2007

These results are supplied for informational purposes only.

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

Endocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh

Euglycaemic glucose clamp: what it can and cannot do, and how to do it

SUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*

Received: 15 December 2004 / Accepted: 16 May 2005 / Published online: 14 September 2005 # Springer-Verlag 2005

SCIENTIFIC DISCUSSION

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T

INSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects

Bioequivalence and Comparative Pharmacodynamics of Insulin Lispro 200 U/mL Relative to Insulin Lispro (Humalog W ) 100 U/mL

Supplementary Online Content

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

Enhancement of oral bioavailability of insulin in humans

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Akio Ohta, Kaori Arai, Ami Nishine, Yoshiyuki Sada, Hiroyuki Kato, Hisashi Fukuda, Shiko Asai, Yoshio Nagai, Takuyuki Katabami and Yasushi Tanaka

SUPPLEMENTARY INFORMATION

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation

Understandable Statistics

Young Seok Song 1, You-Cheol Hwang 2, Hong-Yup Ahn 3, Cheol-Young Park 1

SITA 100 mg (n = 378)

Improved Postprandial Glucose Control Using the InsuPad Device in Insulin- Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control

Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues

Comparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Review Report. July 10, 2015 Pharmaceuticals and Medical Devices Agency

INSULIN 101: When, How and What

hypoglycaemia unawareness keystone 18 July 2014

Clinical Study Synopsis

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The oral meal or oral glucose tolerance test. Original Article Two-Hour Seven-Sample Oral Glucose Tolerance Test and Meal Protocol

Cross-Matches for Bioequivalence Evaluation Division using Needle Free Jet Injector (Comfort-In) and conventional Pen type syringe.

Supplementary Online Content

Insulin sensitivity, its variability and glycaemic outcome:

CONSULTANT PHYSICIAN v SANOFI

Sponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)

Supplementary Figure 1: Steviol and stevioside potentiate TRPM5 in a cell-free environment. (a) TRPM5 currents are activated in inside-out patches

Insulin Secretion and Hepatic Extraction during Euglycemic Clamp Study: Modelling of Insulin and C-peptide data

Tim Heise 1 Kirstine Stender-Petersen. Leszek Nosek 1 Eric Zijlstra

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Supplementary Appendix

A tale of two insulins : Understanding basal insulin therapy in type 2 diabetes Swinnen, S.G.H.A.

Supplementary Online Content

Diabetes Care Publish Ahead of Print, published online November 18, 2008

Evaluation of a glomerular filtration term in the DISST model to capture the glucose pharmacodynamics of an insulin resistant cohort

Time-Action Profile of the Long-Acting Insulin Analog Insulin Glargine (HOE901) in Comparison With Those of NPH Insulin and Placebo

Providing Stability to an Unstable Disease

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine (HOE901) Insulin Glulisine (HMR1964)

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Inhaled Technosphere Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

Supplementary Appendix

A Review of a Family of Ultra-Rapid-Acting Insulins: Formulation Development

SYNOPSIS OF RESEARCH REPORT (PROTOCOL BC20779)

Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial

Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients

5g vs. control, contrast. 10g vs. control, contrast. -3.6e-15 ± 4.3

SUPPLEMENTARY DATA. Supplementary Figure 1. Flow diagram of study selection

Is Degludec the Insulin of Tomorrow?

Dr. M.Mothilal Assistant professor

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)

Association of plasma uric acid with ischemic heart disease and blood pressure:

Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Supplementary Online Content

Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre

A Population Dose Response Model for Inhaled Technosphere Insulin Administered to Healthy Subjects

Immune Modulation of Type1 Diabetes

Biostatistics for Med Students. Lecture 1

Demonstrating that inhaled insulin

Report Reference Guide

Supplementary Appendix

Clinical Study Report AI Final 28 Feb Volume: Page:

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Sponsor / Company: Sanofi Drug substance(s): HOE901-U300 (insulin glargine) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

What is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming

GLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK

Clinical Study Synopsis for Public Disclosure

The importance of good glycaemic

Technical Information Guide

Timely!Insulinization In!Type!2! Diabetes,!When!and!How

Glucose tolerance status was defined as a binary trait: 0 for NGT subjects, and 1 for IFG/IGT

Supplementary Online Content

CLINICAL TRIAL. Keywords Basal bolus treatment, Hypoglycemia, Insulin degludec

Individualizing Therapy int2dm With Insulin

Transcription:

Supplementary Table. Participant characteristics in cohort Cohort Number Sex, Male Female Age, years. (.) Diabetes duration, years.5 (5.) BMI, kg.m. (3.) HbA c, % mmol.mol. (.7) () C-peptide, nmol.l.3 (.) Basal insulin dose, U.kg.day.35 (.) Prandial insulin dose, U.kg.day.3 (.) Data are number of participants, or mean (standard deviation). American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

Supplementary Table. Pharmacokinetic parameters in cohort after multiple doses in steady state Gla-. U.kg Cohort. U.kg Number INS-C max, µu.ml *. ±. 7. ±. INS-t /, h*. ±.3 7.7 ±. INS-AUC, µu.h.ml * 3 ± 57 5 ± 3 INS-AUC 3, µu.h.ml * 3 ± 99 3 ± 7 T 5% -INS-AUC, h (9 ) ( ) T 5% -INS-AUC 3, h ( 3) (3 5) ΔINS, µu.ml, ( 9) (9 7) Swing,. (..)).7 (.5.) *Mean ± SD; median (interquartile range); INS-C maxss INS-C ss ; (INS-C maxss INS-C ss )/INS-C ss ; INS-C max = maximum serum insulin concentration; INS-t / = terminal half-life of serum insulin concentration; INS-AUC /3 = area under the concentration versus time curve from time to /3 hours. Supplementary Table 3. Pharmacodynamic parameters in cohort after multiple doses in steady state Cohort Gla-. U.kg. U.kg Number GIR-AUC, mg.kg * () 379 (35) GIR-AUC 3, mg.kg * 353 () 3 (573) GIR max, mg.kg.min 3. (3..) 3.7 (3.3 5.7) T 5% -GIR-AUC, h ( ) ( ) T 5% -GIR-AUC 3, h ( 3) (3 5) *Mean ± SD; median (interquartile range); GIR-AUC /3 = glucose infusion rate from time to /3 hours; GIR max = maximum smoothed body weight standardized GIR (smoothing factor of.). American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

Supplementary Table. Cumulative time of blood glucose control below thresholds after last administration on day Cohort Cohort Median time (h) BG (mg.dl ) Gla- Gla-. U.kg. U.kg. U.kg. U.kg 5. 9.5 5. 3.3 * 9.3 33.5.3 3. 5 3. 3. 3. 3. *Clamp level plus mg.dl ( mmol.l ). Note, data are right censored. BG, blood glucose. Supplementary Table 5. Last time of blood glucose below thresholds after last administration on day Median time (h) BG (mg.dl ) Cohort Cohort Gla- Gla-. U.kg. U.kg. U.kg. U.kg 5.7 3.7 9.9 35.3 *.5 3. 3. 3. 5 3. 3. 3. 3. *Clamp level plus mg.dl ( mmol.l ). Note, data are right censored. BG, blood glucose. American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

Supplementary Figure. Steady-state study design Clamp Clamp Treatment Treatment Cohort (N=). U.kg -. U.kg - Gla-. U.kg - Gla-. U.kg -. U.kg - Cohort (N=). U.kg -. U.kg - Gla-. U.kg - Washout (5 9 days) Gla-. U.kg -. U.kg - Day Day Day Day American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

Supplementary Figure. INS, GIR and BG profiles after multiple doses in steady state, overall and by participant (cohort ) Individual INS profiles (A), smoothed GIR profiles (B) and smoothed Biostator measured BG profiles (C) for participants in cohort (N=; Gla-. U.kg versus. U.kg ). Summary profiles of INS (D), smoothed GIR (E) and smoothed Biostator measured BG (F) are also provided. Raw data are shown as grey, filled circles. A LOESS smoothing factor of. was applied to all GIR and BG profiles. Summary INS profiles (D) overlay box-plots showing the dispersion of data at each time point: median, interquartile range (inner fences), outer fences and outside values. On INS profile plots, the lower limit of quantification (5. µu.ml ) is displayed for reference. INS, serum insulin concentration; GIR, body weight standardized glucose infusion rate; BG, blood glucose; LOESS, locally weighted regression in smoothing scatterplots. American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

A...3..5..7..9....3..5..7. Gla- INS [µu.ml - ] INS [µu.ml - ] INS [µu.ml - ] INS [µu.ml - ] - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 B Gla- GIR [mg.kg -.min - ] GIR [mg.kg -.min - ]...3..5..7..9....3..5..7. - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 GIR [mg.kg -.min - ] GIR [mg.kg -.min - ] C 5...3..5..7..9....3..5..7. 5 Gla- BG [mg.dl - ] 5 5 BG [mg.dl - ] 5 5 5 5 BG [mg.dl - ] 5 5 BG [mg.dl - ] 5 5-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3-3 - 3 D E F Gla- Gla- Gla- INS [µu.ml - ] GIR [mg.kg -.min - ] BG [mg.dl - ] 5-3 - 3-3 - 3 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

Supplementary Figure 3. INS, GIR and BG profiles after multiple doses in steady state, overall and by participant (cohort ) Individual INS profiles (A), smoothed GIR profiles (B) and smoothed Biostator measured BG profiles (C) for participants in cohort (N=; Gla-. U.kg versus. U.kg ). Summary profiles of INS (D), smoothed GIR (E) and smoothed Biostator measured BG (F) are also provided. Raw data are shown as grey, filled circles. A LOESS smoothing factor of. was applied to all GIR and BG profiles. Summary INS profiles (D) overlay box-plots showing the dispersion of data at each time point: median, interquartile range (inner fences), outer fences and outside values. On INS profile plots, the lower limit of quantification (5. µu.ml ) is displayed for reference. INS, serum insulin concentration; GIR, body weight standardized glucose infusion rate; BG, blood glucose; LOESS, locally weighted regression in smoothing scatterplots. American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc

A..9....3..5..7.. Gla- INS [µu.ml - ] INS [µu.ml - ] INS [µu.ml - ] INS [µu.ml - ] - 3-3 - 3-3- 3-3 - 3-3- 3-3 - 3-3 B Gla- GIR [mg.kg -.min - ] GIR [mg.kg -.min - ]..9....3..5..7.. - 3-3 - 3-3- 3-3 - 3-3- 3-3 - 3-3 GIR [mg.kg -.min - ] GIR [mg.kg -.min - ] C 5..9....3..5..7.. 5 Gla- BG [mg.dl - ] BG [mg.dl - ] 5 5 5 5 5 5 5 5 BG [mg.dl - ] BG [mg.dl - ] 5 5-3- 3-3 - 3-3- 3-3 - 3-3- 3-3 - 3 D E F Gla- Gla- Gla- INS [µu.ml - ] GIR [mg.kg -.min - ] BG [mg.dl - ] 5-3 - 3-3 - 3 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:.337/dc-/-/dc